MIM
IMNM icon

MetLife Investment Management’s Immunome IMNM Stock Holding History

MetLife Investment Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.22M Buy
55,857
+3,823
+7% +$85.1K 0.01% 1308
2025
Q4 		$1.12M Buy
52,034
+9,623
+23% +$169K 0.01% 1364
2025
Q3 		$497K Hold
42,411
– – ﹤0.01% 1809
2025
Q2 		$394K Hold
42,411
– – ﹤0.01% 1797
2025
Q1 		$285K Buy
42,411
+6,792
+19% +$65.2K ﹤0.01% 2000
2024
Q4 		$378K Buy
35,619
+5,354
+18% +$64.7K ﹤0.01% 1952
2024
Q3 		$442K Buy
30,265
+17,053
+129% +$242K ﹤0.01% 1844
2024
Q2 		$160K Buy
+13,212
New +$207K ﹤0.01% 2378

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

MetLife Investment Management's IMNM Position: Q1 2026 in Review

MetLife Investment Management increased its Immunome (IMNM) stake by 7.3% in Q1 2026, buying an estimated $85.1K and bringing the position to 55,857 shares worth $1.22M. The position accounts for 0.01% of the portfolio, ranked #1308.

MetLife Investment Management first reported a position in IMNM in Q2 2024 and has held it in 8 quarters since. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • MetLife Investment Management held 55,857 shares of Immunome worth $1.22M as of Q1 2026.
  • MetLife Investment Management bought 3,823 Immunome shares in Q1 2026, an estimated $85.1K.
  • Immunome made up 0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1308 holding.
  • MetLife Investment Management first reported a position in Immunome in Q2 2024 and has held it in 8 quarters since.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.